Literature DB >> 30197041

A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study.

J Kellogg Parsons1, Peter A Pinto2, Christian P Pavlovich3, Edward Uchio4, Hyung L Kim5, Mikel N Nguyen6, James L Gulley2, Christina Jamieson7, Paul Hsu8, Margarita Wojtowicz2, Howard Parnes2, Jeffrey Schlom2, William L Dahut2, Ravi A Madan2, Renee N Donahue2, H-H Sherry Chow8.   

Abstract

The Immunotherapy to Prevent Progression on Active Surveillance Study is the first trial of immunotherapy for localized prostate cancer. We randomized active surveillance patients to PSA-TRICOM (PROSTVAC) or placebo for 5mo. Final results will be available in 2019.
Copyright © 2018 European Association of Urology. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30197041     DOI： 10.1016/j.euf.2018.08.016

Source DB:  PubMed          Journal:  Eur Urol Focus        ISSN： 2405-4569


  4 in total

Review 1.  Considering the potential for gene-based therapy in prostate cancer.

Authors:  Justin R Gregg; Timothy C Thompson
Journal:  Nat Rev Urol       Date:  2021-02-26       Impact factor: 14.432

Review 2.  Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment.

Authors:  Norihiro Watanabe; Mary Kathryn McKenna; Amanda Rosewell Shaw; Masataka Suzuki
Journal:  Mol Ther       Date:  2020-10-31       Impact factor: 11.454

Review 3.  Vaccines for Non-Viral Cancer Prevention.

Authors:  Cristina Bayó; Gerhard Jung; Marta Español-Rego; Francesc Balaguer; Daniel Benitez-Ribas
Journal:  Int J Mol Sci       Date:  2021-10-09       Impact factor: 5.923

Review 4.  Active surveillance versus nonradical treatment for low-risk men with prostate cancer: a review.

Authors:  Sachin Perera; Jodie McDonald; Isabella Williams; Jonathan O'Brien; Declan Murphy; Nathan Lawrentschuk
Journal:  Prostate Int       Date:  2022-08-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.